GTHR Stock Overview
A biotechnology company, develops molecular assays and therapeutics for the detection and treatment of zoonotic diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
GeneThera, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0001 |
| 52 Week High | US$0.006 |
| 52 Week Low | US$0.000001 |
| Beta | 0 |
| 11 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | n/a |
| 33 Year Change | -99.86% |
| 5 Year Change | -96.00% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| GTHR | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | 2.4% | 0.5% |
| 1Y | n/a | 15.6% | 30.7% |
Return vs Industry: Insufficient data to determine how GTHR performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how GTHR performed against the US Market.
Price Volatility
| GTHR volatility | |
|---|---|
| GTHR Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.9% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: GTHR's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine GTHR's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Tony Milici | www.genethera.net |
GeneThera, Inc., a biotechnology company, develops molecular assays and therapeutics for the detection and treatment of zoonotic diseases. It offers treatments for zoonotic diseases, such as COVID -19 disease; paratuberculosis (Johne’s disease) that is in Stage III clinical phase; mad cow and chronic wasting diseases; and E.coli and salmonella infections, as well as develops vaccine for mycobacterium avium sub paratuberculosis bacteria. The company’s Molecular Robotic/AI Platform and Therapeutic strategy is designed to prevent the spread of disease from animals and allow to better control of zoonotic infectious agents.
GeneThera, Inc. Fundamentals Summary
| GTHR fundamental statistics | |
|---|---|
| Market cap | US$3.53k |
| Earnings (TTM) | -US$681.26k |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs GTHR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GTHR income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$681.26k |
| Earnings | -US$681.26k |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did GTHR perform over the long term?
See historical performance and comparison